U.S. Markets open in 2 hrs 50 mins
  • S&P Futures

    3,923.25
    +19.50 (+0.50%)
     
  • Dow Futures

    31,588.00
    +167.00 (+0.53%)
     
  • Nasdaq Futures

    12,093.25
    +52.75 (+0.44%)
     
  • Russell 2000 Futures

    1,781.80
    +12.00 (+0.68%)
     
  • Crude Oil

    111.66
    +2.09 (+1.91%)
     
  • Gold

    1,825.90
    +1.10 (+0.06%)
     
  • Silver

    21.27
    +0.10 (+0.48%)
     
  • EUR/USD

    1.0588
    +0.0001 (+0.0106%)
     
  • 10-Yr Bond

    3.1940
    0.0000 (0.00%)
     
  • Vix

    27.01
    -0.22 (-0.81%)
     
  • GBP/USD

    1.2260
    -0.0010 (-0.0821%)
     
  • USD/JPY

    136.1370
    +0.6910 (+0.5102%)
     
  • BTC-USD

    21,068.44
    -375.58 (-1.75%)
     
  • CMC Crypto 200

    460.02
    -1.77 (-0.38%)
     
  • FTSE 100

    7,340.60
    +82.28 (+1.13%)
     
  • Nikkei 225

    27,049.47
    +178.17 (+0.66%)
     

Connect Biopharma to Participate at the Jefferies Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Connect Biopharma Holdings Limited
Connect Biopharma Holdings Limited

SAN DIEGO, CA and TAICANG, SUZHOU, China, June 02, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect Biopharma" or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that Dr. Zheng Wei, Co-Founder & Chief Executive Officer, and Steven Chan, Chief Financial Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 am ET.

A live webcast will be available on the Company’s Investor Relations page, accessible here: https://investors.connectbiopharm.com/. A replay will be available on the Company’s website following the event.

About Connect Biopharma Holdings Limited
Connect Biopharma is a global, clinical-stage biopharmaceutical company dedicated to improving the lives of patients with inflammatory diseases through the development of therapies derived from T cell-driven research. It is building a rich pipeline of internally-designed, wholly-owned, small molecules and antibodies using functional cellular assays with T cells to screen and discover potent product candidates against validated immune targets. Its lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. The Company’s second most advanced product candidate, CBP-307, is a modulator of a T-cell receptor known as S1P1 in development for the treatment of UC. Clinical development has begun for its third product candidate, CBP-174, a peripherally acting antagonist of histamine receptor 3, for the treatment of pruritus associated with AD.

With operations in the United States and China, Connect Biopharma is building a rich global pipeline of molecules and antibodies targeting several aspects of T cell biology. For additional information, please visit www.connectbiopharm.com.

IR/PR CONTACTS: 
Lazar FINN Partners
David Carey (IR)
T: +1 (212) 867-1768
david.carey@finnpartners.com 

Glenn Silver (Media)
T: +1 (973) 818-8198
glenn.silver@finnpartners.com

Corporate Contacts:
info@connectpharm.com